Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HCP1904-3 in Essential Hypertension
NCT05199129Phase 3Completed
- Sponsor
- Hanmi Pharmaceutical
- Start
- Nov 2021
- Primary completion
- Sep 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of HCP1904-3 in essential hypertension, sponsored by Hanmi Pharmaceutical. Started Nov 2021; status: completed.
02
Drugs
HCP1904-3
03
Conditions
essential hypertension
Beyond the preview
Go deeper on NCT05199129.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05199129.